Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke - TOAST
Description:
TOAST is a randomized, double-blind, placebo-controlled trial to test whether a low molecular heparinoid (ORG 10172) increases the likelihood of a favorable outcome at 3 months following acute ischemic stroke.
Hypothesis:
The low molecular heparinoid ORG 10172 may improve outcomes at both 7 days and 3 months following acute ischemic stroke more than placebo.
Study Design
Study Design:
Patients Screened: 25624
Patients Enrolled: 1281
Mean Follow Up: 3 months
Mean Patient Age: Mean of 65
Female: 40
Patient Populations:
- 18-85 years old
- Acute or progressing ischemic stroke with symptoms present for more than 1 hour but less than 24 hours
- Prestroke modified Barthel Index of 12 or more
Exclusions:
- Resolution of neurologic symptoms
- An isolated mild neurologic deficit
- Stroke less than 24 hours old with recent progression, coma, or mass effect on baseline CT
- Intracranial blood on CT
- CT evidence of nonvascular cause of symptoms
- Active bleeding
- Major surgery within the previous 24 hours
- Abnormal baseline coagulation studies
- Mean blood pressure greater than 130 mm Hg
- Major organ failure
- Known vasculitis or infective endocarditis
- Complex medical illness or terminal illness
- Confounding neurologic disease
- Allergy to heparin
- Prior participation in TOAST
- Women who are pregnant or lactating
Primary Endpoints:
Favorable outcome at 3 months, defined as a score of I or II on the Glasgow Outcome Scale and a score of 12-20 on the modified Barthel Index.
Secondary Endpoints:
- Favorable outcome at 7 days
- Reducing recurrent stroke within 7 days
- Halting worsening of neurologic deficits within 7 days
- Reducing mortality at 7 days and 3 months
Drug/Procedures Used:
- 7-day course of ORG 10172 titrated to maintain an anti-factor Xa level of 0.6-0.8.
- placebo
Concomitant Medications:
Concomitant use of aspirin, heparin, warfarin, ticlopidine and NSAIDs was prohibited during this period
Principal Findings:
- At 3 months, 482 (75.2%) of patients randomized to ORG 10172 vs. 467 (73.7%) of those in the placebo group had a favorable neurologic outcome, p=0.49
- At 7 days 376 (59.2%) of those in the ORG 10172 vs. 344 (54.3%) of those in the placebo group had favorable neurologic outcomes, p=0.07
- 215 (33.9%) in the ORG 10172 vs. 176 (27.8%) of the placebo group had very favorable neurologic outcome at 7 days, p=0.01
- Serious intracranial bleeding events occurred in 14 patients given ORG 10172 vs. 4 patients in placebo group, p=0.05)
Interpretation:
Among patients with acute ischemic stroke, treatment with ORG 10172 (Danaparoid) demonstrated no significant difference in favorable neurologic outcomes at 3 months compared with placebo. Patients randomized to the ORG 10172 group had a significantly higher rate of very favorable outcomes at 7 days. There was, however, a significant association of ORG 10172 administration and serious intracranial bleeding within 10 days.
References:
The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke. JAMA,1998; 279:1265-1272.
Keywords: Dermatan Sulfate, Heparinoids, Stroke, Chondroitin Sulfates, Heparin, Heparitin Sulfate, Factor Xa
< Back to Listings